1. Destruxin E Decreases Beta-Amyloid Generation by Reducing Colocalization of Beta-Amyloid-Cleaving Enzyme 1 and Beta-Amyloid Protein Precursor.
- Author
-
Itoh, Naohiro, Okochi, Masayasu, Tagami, Shinji, Nishitomi, Kouhei, Nakayama, Taisuke, Yanagida, Kanta, Fukumori, Akio, Jiang, Jingwei, Mori, Kohji, Hosono, Motoko, Kikuchi, Jyunko, Nakano, Yuko, Takinami, Yoshihiko, Dohi, Keiji, Nishigaki, Atsuko, Takemoto, Hiroshi, Minagawa, Kazuyuki, Katoh, Takaaki, Willem, Michael, and Haass, Christian
- Subjects
- *
AMYLOID beta-protein precursor , *DRUG interactions , *AMYLOID beta-protein , *GLYCOPROTEINS ,REPORTING of drug side effects - Abstract
Alzheimer-disease-associated β-amyloid (Aβ) is produced by sequential endoproteolysis of β-amyloid protein precursor (βAPP): the extracellular portion is shed by cleavage in the juxtamembrane region by β-amyloid-cleaving enzyme (BACE)/β-secretase, after which it is cleaved by presenilin (PS)/γ-secretase near the middle of the transmembrane domain. Thus, inhibition of either of the secretases reduces Aβ generation and is a fundamental strategy for the development of drugs to prevent Alzheimer disease. However, it is not clear how small compounds reduce Aβ production without inhibition of the secretases. Such compounds are expected to avoid some of the side effects of secretase inhibitors. Here, we report that destruxin E (Dx-E), a natural cyclic hexadepsipeptide, reduces Aβ generation without affecting BACE or PS/γ-secretase activity. In agreement with this, Dx-E did not inhibit Notch signaling. We found that Dx-E decreases colocalization of BACE1 and βAPP, which reduces β-cleavage of βAPP. Therefore, the data demonstrate that Dx-E represents a novel Aβ-reducing process which could have fewer side effects than secretase inhibitors. Copyright © 2009 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF